Genovis AB (publ.) (STO:GENO)

Sweden · Delayed Price · Currency is SEK

20.35

-0.10 (-0.49%)

Dec 5, 2025, 5:29 PM CET

-18.27% (1Y)

Market Cap	1.35B
Revenue (ttm)	117.66M
Net Income (ttm)	21.18M
Shares Out	66.06M
EPS (ttm)	0.32
PE Ratio	63.04
Forward PE	44.16
Dividend	n/a
Ex-Dividend Date	n/a

Volume	32,637
Average Volume	157,138
Open	20.70
Previous Close	20.45
Day's Range	19.90 - 20.85
52-Week Range	17.10 - 30.45
Beta	2.12
RSI	44.24
Earnings Date	Nov 7, 2025

About Genovis AB (publ.)

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisRE... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1999

Employees 32

Stock Exchange Nasdaq Stockholm

Ticker Symbol GENO

Full Company Profile

Financial Performance

In 2024, Genovis AB (publ.)'s revenue was 131.32 million, a decrease of -17.44% compared to the previous year's 159.07 million. Earnings were 32.92 million, a decrease of -46.48%.

Financial Statements

News

Genovis AB (OSTO:GENO) Q3 2024 Earnings Report Preview: What to Expect

1 year ago - GuruFocus